ABSTRACT
Objective To explore the therapeutic effect of bismuth potassium citrate combined with famotidine on peptic ulcer and its effects on the levels of lipid peroxide (LPO),malondialdehyde (MDA) and somatostatin (SS).Methods One hundred and fifty patients with peptic ulcer who were treated in Cixi Cilin Hospital from January 2018 to May 2019 were randomly divided into famotidine group and combined treatment group,with 75 cases in each group.Famotidine group was treated with famotidine,while bismuth potassium citrate combined with famotidine was used in combined treatment group.H+-K+-ATP ase activity,gastric acid-base value and gastric acid secretion function were detected in two groups.The levels of tumor necrosis factor-ot (TNF-α),interleukin-7 (IL-7),hypersensitive C-reactive protein (hs-CRP) were detected by ELISA,T lymphocyte subsets were detected by flow cytometry,and the levels of T lymphocyte subsets were detected by immunotransmission turbidimetry.The levels of LPO,MDA and SS were measured,and the therapeutic effect,ulcer healing and adverse reactions were compared between two groups.Results After treatment,the activity of H+-K+-ATP ase in the combined treatment group was lower than that in the famotidine group [(2.54 ± 0.41) μmol/min vs.(2.87 ± 0.50) μmol/min],the acid-base value in stomach was higher than that in the famotidine group (5.56 ± 1.19 vs.4.77 ± 0.89),and there were significant differences (P ＜ 0.05).After treatment,the levels of maximum gastric acid excretion after pentagastrin stimulation (MAO),peak gastric acid output (PAO),basal acid output (BAO),TNF-α,IL-17,hs-CRP,CD8+,LPO and MDA in combined treatment group were lower than those in famotidine group [(8.22 ± 1.76) mmol/h vs.(10.53 ± 2.21) mmol/h,(11.88 ± 2.51)mmol/h vs.(14.79 ± 2.76) mmol/h,(4.11 ± 1.32) mmol/h vs.(5.54 ± 1.49) mmol/h,(4.76 ± 1.52) ng/L vs.(6.91 ± 1.61) ng/L,(18.37 ± 3.25) ng/L vs.(22.83 ± 3.62) ng/L,(6.41 ± 1.81) mg/L vs.(8.67 ± 2.15) mg/L,0.287 6 ± 0.030 5 vs.0.325 5 ± 0.032 4,(0.06 ± 0.02) U/mg vs.(0.09 ± 0.03) U/mg,(10.19 ± 1.86) μmol/L vs.(13.25 ± 2.03) μmol/L],while the levels of CD3+,CD4+,SS were higher than those in the famotidine group [0.523 6 ± 0.040 9 vs.0.476 3 ± 0.039 5,0.356 6 ± 0.035 2 vs.0.315 8 ± 0.033 9,(14.59 ± 2.67)ng/L vs.(10.36 ± 2.31) ng/L],and there were significant differences (P＜0.05).The total effective rate and ulcer healing rate in combined treatment group were higher than those in famotidine group [93.33％ (70/75) vs.80.00％ (60/75),94.67％ (71/75) vs.82.67％ (62/75)] (P＜ 0.05).The incidence of adverse reactions in combined treatment group was slightly higher than that in famotidine group [16.00％(12/75)vs.13.33％ (10/75)],but there was no significant difference between the two groups (P＞0.05).Conclusions Bismuth potassium citrate combined with famotidine in the treatment of peptic ulcer patients can improve gastric acid secretion function,regulate gastric acid-base value,inhibit inflammatory response,improve immune function,and reduce oxidative stress injury.
ABSTRACT
Objective@#To explore the therapeutic effect of bismuth potassium citrate combined with famotidine on peptic ulcer and its effects on the levels of lipid peroxide (LPO), malondialdehyde (MDA) and somatostatin (SS).@*Methods@#One hundred and fifty patients with peptic ulcer who were treated in Cixi Cilin Hospital from January 2018 to May 2019 were randomly divided into famotidine group and combined treatment group, with 75 cases in each group. Famotidine group was treated with famotidine, while bismuth potassium citrate combined with famotidine was used in combined treatment group. H+-K+-ATP ase activity, gastric acid-base value and gastric acid secretion function were detected in two groups. The levels of tumor necrosis factor-α (TNF-α), interleukin-7 (IL-7), hypersensitive C-reactive protein (hs-CRP) were detected by ELISA, T lymphocyte subsets were detected by flow cytometry, and the levels of T lymphocyte subsets were detected by immunotransmission turbidimetry. The levels of LPO, MDA and SS were measured, and the therapeutic effect, ulcer healing and adverse reactions were compared between two groups.@*Results@#After treatment, the activity of H+-K+-ATP ase in the combined treatment group was lower than that in the famotidine group [(2.54 ± 0.41) μmol/min vs. (2.87 ± 0.50) μmol/min], the acid-base value in stomach was higher than that in the famotidine group(5.56 ± 1.19 vs. 4.77 ± 0.89), and there were significant differences (P<0.05). After treatment, the levels of maximum gastric acid excretion after pentagastrin stimulation (MAO), peak gastric acid output (PAO), basal acid output (BAO), TNF-α, IL-17, hs-CRP, CD8+, LPO and MDA in combined treatment group were lower than those in famotidine group [(8.22 ± 1.76) mmol/h vs. (10.53 ± 2.21) mmol/h, (11.88 ± 2.51)mmol/h vs. (14.79 ± 2.76) mmol/h, (4.11 ± 1.32) mmol/h vs. (5.54 ± 1.49) mmol/h, (4.76 ± 1.52) ng/L vs.(6.91 ± 1.61) ng/L, (18.37 ± 3.25) ng/L vs. (22.83 ± 3.62) ng/L, (6.41 ± 1.81) mg/L vs. (8.67 ± 2.15) mg/L, 0.287 6 ± 0.030 5 vs. 0.325 5 ± 0.032 4, (0.06 ± 0.02) U/mg vs. (0.09 ± 0.03) U/mg, (10.19 ± 1.86) μmol/L vs. (13.25 ± 2.03) μmol/L], while the levels of CD3+, CD4+, SS were higher than those in the famotidine group [0.523 6 ± 0.040 9 vs. 0.476 3 ± 0.039 5, 0.356 6 ± 0.035 2 vs. 0.315 8 ± 0.033 9, (14.59 ± 2.67) ng/L vs. (10.36 ± 2.31) ng/L], and there were significant differences (P<0.05). The total effective rate and ulcer healing rate in combined treatment group were higher than those in famotidine group [93.33%(70/75) vs. 80.00%(60/75), 94.67%(71/75) vs. 82.67%(62/75)] (P<0.05). The incidence of adverse reactions in combined treatment group was slightly higher than that in famotidine group [16.00%(12/75) vs. 13.33%(10/75)], but there was no significant difference between the two groups (P>0.05).@*Conclusions@#Bismuth potassium citrate combined with famotidine in the treatment of peptic ulcer patients can improve gastric acid secretion function, regulate gastric acid-base value, inhibit inflammatory response, improve immune function, and reduce oxidative stress injury.
ABSTRACT
Objective To explore the clinical efficacy of anti-helicobacter pylori (HP) treatment on patients with type 2 diabetes mellitus and HP infection.Methods A total of 112 type 2 Diabetes patients were diagnosed with HP infection in Combine Traditional Chinese and Western Medicine Hospital of Taizhou from April 2012 to June 2016.These patients were divided into control and treatment group based on the preprandial blood glucose averages from lower to higher hierarchy.Thus,there were 56 patients in each of the two groups.The control group was given Motilium and Talcid for gastric symptoms in addition to anti-diabetes treatment,while the treatment was administered the same treatments as well as the quadruple anti-HP therapy (omeprazole,amoxicillin,clarithromycin and colloidal-bismuth-subcitrate,with Talcid stopped while colloidal-bismuth-subcitrate was administered).The anti-HP lasted for 14 days.The two groups were compared the gastric symptoms,the blood glucose levels,and the HbA1c one month after treatment.Half a year and one year post treatment,the two groups were compared the gastric mucus signs under gastroscopy.Results The improvement rates after treatment with the treatment group in abdominal pain,bloating,regurgitation,belching and diarrhea/constipation were 88.5％ (23/26),83.3％ (25/30),74.1％ (20/27),83.9％ (26/31),82.6％ (19/23),respectively,and with the control group being 29.2％(7/24),32.1％(9/28),28％(7/25),30.3％(10/33),18.2％ (4/22),respectively.The differences between the two groups were significant (x2=8.06,6.62,3.92,7.65,6.66,P＜0.05 or P＜0.01).The control group did not show significant changes in preprandial glucose levels,the glucose levels two hours post meals and the HbA1c(P＞0.05) while the treatment group showed statistically significant changes(P＜0.05 or P＜0.01).The differences in the three indicators after treatment between the two groups were significant (t =4.07,7.85,4.16,P＜ 0.05).The Gastric mucus signs under gastroscopy showed improvements in both groups after treatment.The improvement rates with the treatment group were 86.2％(25/29),86.7％ (13/15),77.8％ (14/18),72.7％ (8/11) respectively,with the control group being 36％ (9/16),27.3％ (3/11),13.3％ (2/15),14.3％ (1/7),respectively.The differences between the two groups were significant (x2 =6.71,4.12,4.38,3.85,P ＜ 0.05 or P＜ 0.01).The effectiveness rate,which was based on combined improvements in gastric symptoms,glucose levels and gastric mucus signs,was 76.8％ with the treatment group and 32.1％ with the control group.The difference was statistically significant (x2 =6.78,P＜0.01).Conclusion Anti-HP treatment can relieve the gastric symptoms,stabilize the glucose levels,and help to reverse the changed gastric mucus.All these can reduce the complications of the diabetes and improve the prognosis of the patients.
ABSTRACT
Objective To observe the effect and safety of helicobacter pylori eradication by doxycycline, levofloxacin,bismuth potassium citrate combined with omeprazole.Methods 240 patients who infected helicobacter pylori were selected,and were randomly divided into four groups:treatment group(doxycycline,levofloxacin,bismuth potassium citrate,omeprazole),control group A(doxycycline,levofloxacin,omeprazole),control group B(amoxicillin, clarithromycin,bismuth potassium citrate,omeprazole),control group C (amoxicillin,clarithromycin,omeprazole), 60 patients in each group.Helicobacter pylori eradication treatment for 7 days,patients with gastritis stop after the course of the treatment,peptic ulcer patients continue taking omeprazole 5 weeks after 7 days treatment.All patients stopped medicine 2 weeks accepted 14 carbon breath test.And adverse events were investigated.Results In the treatment group and the control group A,B,C,the helicobacter pylori eradication rates were 93.3%,80.0%,91.7%, 75.0%.Compared with group A,the treatment group helicobacter pylori eradication rate increased significantly(χ2 =4.61,P 0.05).Compared with the treatment group,group B had high inci-dence of oral odor(χ2 =6.56,P <0.05).Compared with the treatment group,group C had high incidence of oral odor (χ2 =5.46,P <0.05).Conclusion Doxycycline,levofloxacin,bismuth potassium citrate combined with omeprazole can improve the helicobacter pylori eradication rate significantly,and with low price,has little side effect,no need of penicillin skin test,can used for the patients poverty or allergic to penicillin.
ABSTRACT
Objective:To study the molecular composition of bismuth potassium citrate. Methods:The content of bismuth was de-termined using a volumetric method, the content of potassium was determined by atomic absorption spectrometry, and the content of cit-rate root was determined by ion chromatography. The structure was predicted using 1 HNMR and the crystal structure was studied using X-diffraction test and scanning electron microscopy. The changes in the percentage ratio of the three components were investigated by accelerated stability tests. Results:On the dried basis, the percentage of the three molecular components was bismuth of 35%-38%, potassium of 7%-11% and root citrate of 49%-52%. The NMR spectra and the data indicated that the product had three isomers with the molecular structure of bismuth∶potassium∶root citrate=2∶2∶2. The X-diffraction test and SEM showed that the three forms of amor-phous, monocrystalline and polycrystalline might exist. The percentage ratio of the three elements before and after the stability test was basically stable. Conclusion:Bismuth potassium citrate may have three crystal forms with the percentage of the three structure parts within a certain range, and the structure is relatively stable.
ABSTRACT
Objective: To investigate the clinical efficacy and safety of compound bismuth potassium citrate capsules(CBPCC) combined with omeprazole capsules in eradication of Helicobacter pylori (H. pylori) infection. Methods: A total of 240 patients with gastric H. pylori infection were enrolled in this double-blinded, randomized controlled study. Patients in group A(control group) were given a combination of bismuth potassium citrate/tinidazole/clarithromycin tablets and ormprazole capsule(n= 120); those in group B(treatment group) were given compound bismuth potassium citrate capsules and ormprazole capsules (n = 120). H. pylori eradication rates and clinical safety of both treatment regimens were analyzed using SAS 6.12 software system. Results: A total of 236 patients from 6 resreach centers completed in this study, with 117 in group A and 119 in group B. Two patients in the contol group and 8 in the treatment group did not complete the experiment; six patients in the control group were excluded due to other reasons. There were 236 patients entered full analysis sets(FAS), 220 entered per protocol set (PPS), and 236 entered safety analysis sets (SS). FAS showed that the eradication rates of H. pylori were 84.87% in group B and 74.36% in group A(P 0.05), with no severe adverse event found in both groups. The treatment regimen in group B was more cost-effective than that in group A(P<0.05). Conclusion: This study demonstrates that compound bismuth potassium citrate capsules combined with omeprazole capsules have a high efficacy in eradication of H. pylori infection, and it is safe, cost-effective and worth popularizing in clinic.